A Study of SGN-STNV in Advanced Solid Tumors

Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!

a study on Lung Cancer Non-Small Cell Lung Cancer Breast Cancer Ovarian Cancer Cervical Cancer Endometrial Cancer Esophageal Cancer Gastroesophageal Junction Cancer Stomach Cancer Colorectal Cancer Colorectal Tumor Pancreatic Cancer Appendiceal Adenocarcinoma Pseudomyxoma Peritonei Solid Tumor

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
estimated completion
Principal Investigator
by Pamela Munster (ucsf)
Headshot of Pamela Munster
Pamela Munster

Description

Summary

This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.

Official Title

A Phase 1 Study of SGN-STNV in Advanced Solid Tumors

Details

The study will include dose escalation (Part A) and dose expansion (Part B), with multiple disease-specific cohorts and a biology cohort in dose expansion. The biology cohort will require additional biopsies. At the completion of dose escalation, up to 5 disease specific expansion cohorts and 1 biology expansion cohort may be activated by the sponsor in consultation with the Safety Monitoring Committee (SMC). Expansion cohorts in Part B will enroll subjects with selected tumors that are eligible for enrollment in Part A. The dose(s) to be examined in Part B will be at or below the maximum tolerated dose and/or the recommended dose determined in Part A. The recommended dose and/or schedule may differ between cohorts.

Keywords

Carcinoma, Non-Small Cell Lung HER2 Negative Breast Neoplasms Ovarian Neoplasms Uterine Cervical Neoplasms Endometrial Neoplasms Esophageal Neoplasms Gastroesophageal Junction Carcinoma Stomach Neoplasms Colorectal Neoplasms Exocrine Pancreatic Adenocarcinoma Appendiceal Adenocarcinoma Pseudomyxoma Peritonei NSCLC Non-Small Cell Lung Cancer HER2-Negative Breast Cancer High-Grade Serous Ovarian Cancer HGSOC Ovarian Cancer Cervical Cancer Endometrial Cancer Esophageal Cancer Gastric Cancer GEJ Carcinoma Colorectal Cancer Seattle Genetics Carcinoma Neoplasms Adenocarcinoma Breast Neoplasms Carcinoma, Non-Small-Cell Lung SGN-STNV

Eligibility

You can join if…

Open to people ages 18 years and up

  • Disease indication
  • Must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies and should have no appropriate standard-of-care therapeutic option.
  • Non-small cell lung cancer (NSCLC)
  • HER2 negative breast cancer
  • Ovarian cancer
  • Cervical cancer
  • Endometrial cancer
  • Esophageal cancer
  • Gastric cancer and GEJ carcinoma
  • Colorectal cancer
  • Exocrine pancreatic adenocarcinoma
  • Appendiceal adenocarcinoma and pseudomyxoma peritonei of unknown origin
  • Participants enrolled in the following study parts should have a tumor site accessible for biopsy and agree to biopsy as follows:
  • Disease-specific expansion cohorts: pre-treatment biopsy
  • Biology expansion cohort: pretreatment biopsy and additional on-treatment biopsy during Cycle 1
  • Measurable disease per the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) at baseline
  • An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Adequate renal, hepatic, and hematologic function

You CAN'T join if...

  • History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy.
  • Known active central nervous system metastases
  • Carcinomatous meningitis
  • Previous receipt of monomethylauristatin E (MMAE)-containing drugs
  • Pre-existing neuropathy ≥ Grade 2 per the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
  • Any uncontrolled ≥ Grade 3 (per the NCI CTCAE, Version 5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of SGN-STNV

There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.

Locations

  • University of California at San Francisco accepting new patients
    San Francisco California 94158 United States
  • Angeles Clinic and Research Institute, The accepting new patients
    Los Angeles California 90025 United States

Lead Scientist at University of California Health

  • Pamela Munster (ucsf)
    Professor, Medicine, School of Medicine. Authored (or co-authored) 139 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Seagen Inc.
ID
NCT04665921
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 315 study participants
Last Updated